Medicines information in medical journal advertising in Australia, Malaysia and the United States: A comparative cross-sectional study

Noordin Othman, Agnes Vitry, Elizabeth Ellen Roughead

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: The aim of this study was to compare the provision of medicines information in medical journal advertising in Australia, Malaysia and the United States. Methods: A consecutive sample of 85 unique advertisements from each country was selected from the advertisements published between January 2004 to December 2006 in three widely circulated medical journals and one prescribing reference manual. The availability of brand name and generic name, indication, contraindications, dosage, side-effects, warnings, interactions and precautions was compared between the three countries. Results: We examined 255 distinct advertisements for 136 pharmaceutical products. Journal advertising in Australia, Malaysia and the US usually provided brand names and generic names (range 96 -100%). Information on dosage was significantly less likely to be mentioned (32%) in the US than in Australia (92%) and Malaysia (48%) (P < 0.001). Warning information was significantly less likely to be provided in Australia (5%) than in the US (81%) and Malaysia (9%) (P < 0.001). Apart from information on brand name, generic name, warnings and dosage, other product information significantly less likely to be provided in journal advertising in Malaysia than in Australia and the US (P < 0.001). Similar trends in the provision of product information for the same medicines published in these countries were noted. Brand name and generic name were always provided in the three countries (100%). However, information on the negative effects of medicines was less frequently provided in Malaysia than in Australia and the US. Conclusions: Journal advertising in Australia, Malaysia and the US failed to provide complete product information. Low quality of information provided in Malaysia indicates the need for effective regulation of provision of medicines information in journal advertising. Different standards of medicines information provided in these three countries suggest that pharmaceutical promotion needs to be better controlled at the international level.

LanguageEnglish
Pages11-18
Number of pages8
JournalSouthern Med Review
Volume3
Issue number1
Publication statusPublished - 1 Feb 2010
Externally publishedYes

Keywords

  • Australia
  • Malaysia
  • Pharmaceutical advertisements
  • Promotion
  • Regulation

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Health Policy

Cite this

@article{83b7b6a0b1da4df98a1b38b76d3c3032,
title = "Medicines information in medical journal advertising in Australia, Malaysia and the United States: A comparative cross-sectional study",
abstract = "Objective: The aim of this study was to compare the provision of medicines information in medical journal advertising in Australia, Malaysia and the United States. Methods: A consecutive sample of 85 unique advertisements from each country was selected from the advertisements published between January 2004 to December 2006 in three widely circulated medical journals and one prescribing reference manual. The availability of brand name and generic name, indication, contraindications, dosage, side-effects, warnings, interactions and precautions was compared between the three countries. Results: We examined 255 distinct advertisements for 136 pharmaceutical products. Journal advertising in Australia, Malaysia and the US usually provided brand names and generic names (range 96 -100{\%}). Information on dosage was significantly less likely to be mentioned (32{\%}) in the US than in Australia (92{\%}) and Malaysia (48{\%}) (P < 0.001). Warning information was significantly less likely to be provided in Australia (5{\%}) than in the US (81{\%}) and Malaysia (9{\%}) (P < 0.001). Apart from information on brand name, generic name, warnings and dosage, other product information significantly less likely to be provided in journal advertising in Malaysia than in Australia and the US (P < 0.001). Similar trends in the provision of product information for the same medicines published in these countries were noted. Brand name and generic name were always provided in the three countries (100{\%}). However, information on the negative effects of medicines was less frequently provided in Malaysia than in Australia and the US. Conclusions: Journal advertising in Australia, Malaysia and the US failed to provide complete product information. Low quality of information provided in Malaysia indicates the need for effective regulation of provision of medicines information in journal advertising. Different standards of medicines information provided in these three countries suggest that pharmaceutical promotion needs to be better controlled at the international level.",
keywords = "Australia, Malaysia, Pharmaceutical advertisements, Promotion, Regulation",
author = "Noordin Othman and Agnes Vitry and Roughead, {Elizabeth Ellen}",
year = "2010",
month = "2",
day = "1",
language = "English",
volume = "3",
pages = "11--18",
journal = "Southern Med Review",
issn = "1174-2704",
number = "1",

}

Medicines information in medical journal advertising in Australia, Malaysia and the United States : A comparative cross-sectional study. / Othman, Noordin; Vitry, Agnes; Roughead, Elizabeth Ellen.

In: Southern Med Review, Vol. 3, No. 1, 01.02.2010, p. 11-18.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Medicines information in medical journal advertising in Australia, Malaysia and the United States

T2 - Southern Med Review

AU - Othman, Noordin

AU - Vitry, Agnes

AU - Roughead, Elizabeth Ellen

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Objective: The aim of this study was to compare the provision of medicines information in medical journal advertising in Australia, Malaysia and the United States. Methods: A consecutive sample of 85 unique advertisements from each country was selected from the advertisements published between January 2004 to December 2006 in three widely circulated medical journals and one prescribing reference manual. The availability of brand name and generic name, indication, contraindications, dosage, side-effects, warnings, interactions and precautions was compared between the three countries. Results: We examined 255 distinct advertisements for 136 pharmaceutical products. Journal advertising in Australia, Malaysia and the US usually provided brand names and generic names (range 96 -100%). Information on dosage was significantly less likely to be mentioned (32%) in the US than in Australia (92%) and Malaysia (48%) (P < 0.001). Warning information was significantly less likely to be provided in Australia (5%) than in the US (81%) and Malaysia (9%) (P < 0.001). Apart from information on brand name, generic name, warnings and dosage, other product information significantly less likely to be provided in journal advertising in Malaysia than in Australia and the US (P < 0.001). Similar trends in the provision of product information for the same medicines published in these countries were noted. Brand name and generic name were always provided in the three countries (100%). However, information on the negative effects of medicines was less frequently provided in Malaysia than in Australia and the US. Conclusions: Journal advertising in Australia, Malaysia and the US failed to provide complete product information. Low quality of information provided in Malaysia indicates the need for effective regulation of provision of medicines information in journal advertising. Different standards of medicines information provided in these three countries suggest that pharmaceutical promotion needs to be better controlled at the international level.

AB - Objective: The aim of this study was to compare the provision of medicines information in medical journal advertising in Australia, Malaysia and the United States. Methods: A consecutive sample of 85 unique advertisements from each country was selected from the advertisements published between January 2004 to December 2006 in three widely circulated medical journals and one prescribing reference manual. The availability of brand name and generic name, indication, contraindications, dosage, side-effects, warnings, interactions and precautions was compared between the three countries. Results: We examined 255 distinct advertisements for 136 pharmaceutical products. Journal advertising in Australia, Malaysia and the US usually provided brand names and generic names (range 96 -100%). Information on dosage was significantly less likely to be mentioned (32%) in the US than in Australia (92%) and Malaysia (48%) (P < 0.001). Warning information was significantly less likely to be provided in Australia (5%) than in the US (81%) and Malaysia (9%) (P < 0.001). Apart from information on brand name, generic name, warnings and dosage, other product information significantly less likely to be provided in journal advertising in Malaysia than in Australia and the US (P < 0.001). Similar trends in the provision of product information for the same medicines published in these countries were noted. Brand name and generic name were always provided in the three countries (100%). However, information on the negative effects of medicines was less frequently provided in Malaysia than in Australia and the US. Conclusions: Journal advertising in Australia, Malaysia and the US failed to provide complete product information. Low quality of information provided in Malaysia indicates the need for effective regulation of provision of medicines information in journal advertising. Different standards of medicines information provided in these three countries suggest that pharmaceutical promotion needs to be better controlled at the international level.

KW - Australia

KW - Malaysia

KW - Pharmaceutical advertisements

KW - Promotion

KW - Regulation

UR - http://www.scopus.com/inward/record.url?scp=77952755518&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 11

EP - 18

JO - Southern Med Review

JF - Southern Med Review

SN - 1174-2704

IS - 1

ER -